OXB Oxford BioMedica PLC

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD
EN
06/10/2020

Underlying

OXBOxford BioMedica PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oxford BioMedica PLC

 PRESS RELEASE
Free
OXB Oxford BioMedic...

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene The...

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs. This recognition demonstrates OXB’s excellence in quality, inn...

October 29, 2025 1 EN
 PRESS RELEASE
Free
OXB Oxford BioMedic...

OXB to participate in upcoming investor conferences and events

OXB to participate in upcoming investor conferences and events OXB to participate in upcoming investor conferences and events Oxford, UK – 27 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that members of its senior management team, including Dr. Frank Mathias, Chief Executive Officer, and Dr. Lucy Crabtree, Chief Financial Officer, will participate in the following upcoming investor conferences and events. Details are provided below. Conferences Stifel Healthcare Conference (New York) Date: 11 November 2025Fireside chat: 13...

October 27, 2025 1 EN
 PRESS RELEASE
Free
OXB Oxford BioMedic...

OXB expands US footprint with acquisition of commercial-scale viral ve...

OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client demand Strengthens OXB’s global CDMO network and enhances service offering for existing and prospective clientsSupports existing near and medium-term financial guidance Oxford, UK – 7 October 2025: OXB (LSE: OXB), a global quality and innova...

October 7, 2025 1 EN
Free Trial
OXB Oxford BioMedic...

Oxford BioMedica: 1 director

A director at Oxford BioMedica bought 67,000 shares at 450p and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

OXB OXFORD BIOMEDICA PLC
08/15/25 August 15, 2025 1 EN
 PRESS RELEASE
Free
OXB Oxford BioMedic...

AGM Update

AGM Update Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, provides an update to coincide with its Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK. OXB has demonstrated strong commercial momentum and made good operational and commercial progress in the year 2025 to date, as it continues to provide viral vector manufacturing services to a diversified portfolio of clients. The Company remains on track to deliver the outlook set out in the Preliminary Results for the year ended 31 Decem...

June 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch